Skip to main content

Table 5 DNA Methyltransferase inhibitors in clinical trials

From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Study Agents Other agents Disease Dosage Clinical trails No Pts Response Reference
decitabine GO Elderly, untreated AML 20 mg/m2 IV ×5d, GO 3 mg/m2 IV × 1 d 5 Phase II 33 CR/CRp: 42% [39]
decitabine GO Relapsed and refractory AML 20 mg/m2 IV ×5d retrospective 79 CR/CRp: 21% [40]
Azacytidine   Elderly relapsed and refractory AML 75 mg/m2/d IV, d1-7 retrospective 184 CR/CRi: 10% [41]
Azacytidine gemtuzumab ozogamicin (GO) high-risk AML 75 mg/m2/d IV, d1-7 retrospective 56 CR/CRi: 10% [42]
Azacytidine Bortezomib Relapsed and refractory AML 75 mg/m2/d IV, d1-7 Phase I 23 CR/CRi: 21% [43]
  1. Abbreviations: GO: gemtuzumab ozogamycin; CR: complete remission; CRi: CR with incomplete count recovery; CRp: CR without platelet recovery; MTD: maximal tolerated dose;